TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04647019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild blueberry powder
Description: 22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: 22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
Study: NCT04649710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05090982

Intervention type: OTHER
Intervention: Audio recordings during the consultations
Description: 50 patients with audio recordings of the consultation

Intervention type: OTHER
Intervention: Audio recordings during the consultations and test of the shared medical decision-making tool for modification
Description: 50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
Study: NCT05566054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
Study: NCT06221254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COBMINDEX digital application
Description: COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.
Study: NCT06512480

Intervention type: PROCEDURE
Intervention: colonic resection
Description: colonic resection with the Hugo RAS robotic platform.
Study: NCT05090982

Intervention type: OTHER
Intervention: Audio recordings during the consultations and test of the shared medical decision-making tool for validation
Description: 50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.
Study: NCT05687617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: 0,25mg/kg IV at the start of the surgery,
Study: NCT06170307

Intervention type: OTHER
Intervention: two-dimensional speckle tracking echocardiography
Description: The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.

Intervention type: OTHER
Intervention: two-dimensional speckle tracking echocardiography
Description: The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.
Study: NCT05187598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effective communication training in perinatal patient safety
Description: Students will be given theoretical training, group discussion will be made over sample videos, and students will participate in the standard participant practice and a post-analysis session will be held.
Study: NCT06781944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Oral cyclophosphamide will be given for 30 days in month 2, 4, 6.~The dosage is adjusted based on the age and renal function (rounded down to the nearest 25 mg, max 100 mg/day, Cyclophosphamide tablets should not be split; if necessary, alternating doses of 50 mg/day and 100 mg/day can be used):~* 2.0 mg/kg/d in patients \< 65 years with eGFR ≥60ml/min~* 1.5 mg/kg/d in patients \< 65 years with eGFR\<60ml/min~* 1.5 mg/kg/d in patients ≥ 65 years with eGFR ≥60ml/min~* 1.0 mg/kg/d in patients ≥ 65 years with eGFR\<60ml/min

Intervention type: DRUG
Group type: OTHER
Intervention: Glucocorticoids
Description: Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days.
Study: NCT06781320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint
Description: the patients will receive a stabilization splint fabricated using a fully digital workflow includes:~Intraoral scanning of maxillary and mandibular arches to create a digital model.~Jaw tracking using the Zebris JMA system to record mandibular movements. CAD design of the splint using Exocad software. Fabrication of the splint via 3D printing technology. The FD-SS is designed to provide optimal occlusal stabilization, reduce TMJ stress, and minimize enamel wear over 6 months.~Or the patient will receive stabilization splint fabricated using conventional methods. The intervention includes:~Taking alginate impressions of maxillary and mandibular arches to create plaster casts.~Jaw registration using a Lucia jig and semi-adjustable articulator for proper occlusal adjustment.~Manual fabrication of the splint using polymethyl methacrylate (PMMA) resin. The C-SS is designed to achieve occlusal stabilization and symptom relief for TMD patients over 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stabilization splint
Description: the patients will receive a stabilization splint fabricated using a fully digital workflow includes:~Intraoral scanning of maxillary and mandibular arches to create a digital model.~Jaw tracking using the Zebris JMA system to record mandibular movements. CAD design of the splint using Exocad software. Fabrication of the splint via 3D printing technology. The FD-SS is designed to provide optimal occlusal stabilization, reduce TMJ stress, and minimize enamel wear over 6 months.~Or the patient will receive stabilization splint fabricated using conventional methods. The intervention includes:~Taking alginate impressions of maxillary and mandibular arches to create plaster casts.~Jaw registration using a Lucia jig and semi-adjustable articulator for proper occlusal adjustment.~Manual fabrication of the splint using polymethyl methacrylate (PMMA) resin. The C-SS is designed to achieve occlusal stabilization and symptom relief for TMD patients over 6 months.
Study: NCT06781567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG146
Description: HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
Study: NCT06779825

Intervention type: COMBINATION_PRODUCT
Intervention: fMRI Neurofeedback attention task
Description: Neurofeedback is an attentive task where participants are shown their real-time brain signals while in the scanner with the use of a representation, such as a rocket moving towards a portal. Participants are able to increase this brain signal by more purposefully engaging certain brain regions, and this is reflected in the representation that they see. Ultimately, this study is interested in whether neurofeedback can replicate the effects of stimulant medication in ADHD.
Study: NCT06781554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Small Joints Collagen Medical Device
Description: The infiltrations will be performed using 2.5ml syringes and 26 gauge/13mm needles under complete aseptic conditions. The first 3 infiltrations will be carried out at both intra- and peri-articular levels by injecting MD-Small Joints Collagen Medical Device into the trapeziometacarpal joint until a counter-pressure is felt, preventing further penetration of the liquid; the remaining quantity (usually about 1ml) will be injected at the peri-articular level by retracting the needle tip. The fourth and fifth infiltrations will be performed only at the peri-articular level.
Study: NCT06779877

Intervention type: PROCEDURE
Intervention: Percutaneous dilatational tracheostomy
Description: Percutaneous dilatational tracheostomy

Intervention type: PROCEDURE
Intervention: Percutaneous dilatational tracheostomy
Description: Percutaneous dilatational tracheostomy

Intervention type: DIAGNOSTIC_TEST
Intervention: The optic nerve sheath diameter measurement method by ultrasonography
Description: The optic nerve sheath diameter measurement method by ultrasonography-Determine intracranial pressure.

Intervention type: DIAGNOSTIC_TEST
Intervention: The optic nerve sheath diameter measurement method by ultrasonography
Description: The optic nerve sheath diameter measurement method by ultrasonography-Determine intracranial pressure.
Study: NCT06780553

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomic profiling
Description: Proteomic profiling as a diagnostic tool in the face of suspected extrahepatic cholangiocarcinoma stenosis
Study: NCT06782360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Neurostimulation
Description: The stimulation frequency, pulse width, and amplitude will be varied in order to determine the optimal stimulation conditions for elongating the period of peak subject performance during the experimental tasks. Amplitude, pulse width, and frequency meet or exceed International Electrotechnical Commission (IEC) 60601-2-10:2016 requirements. The amplitude range specified is selectable for either channel with any frequency and pulse width combination. We will test an amplitude range of 0 mA - 5.0 mA. We will test a frequency range of 1 Hz - 150 Hz. We will test a pulse width range of 50 μs - 750 μs. The study coordinator should apply neurostimulation when the reported cognitive state metric corresponding to the performance task reaches different thresholds. These thresholds will be determined before execution of the study and will be chosen to maximize the likelihood of discovering an optimal trigger for neurostimulation based on reported cognitive state.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Modulation of stimulation frequency and amplitudes outside of the known physiological effective ranges during intervention periods.
Study: NCT06780462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids + Rivaroxaban
Description: Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids alone
Description: Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market)
Study: NCT05711901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efferon LPS
Description: Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
Study: NCT06780280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground Walking
Description: Overground walking with an exoskeleton
Study: NCT05726162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback-based music program
Description: The investigators will provide biofeedback-based music, which incorporates the patient's respiratory information. In a biofeedback-based music group, the patient performs an active respiratory intervention session, which induces a slow breathing pattern. If breathing has been slow enough, the automatic mode is activated to provide music based on patient's own breathing pattern. It automatically will be terminated 30 minutes after intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The investigators will provide noise-canceling earplugs to minimize bias from noise in the ward.
Study: NCT06782165

Intervention type: PROCEDURE
Intervention: Arthroscopy & saline irrigation alone
Description: Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly

Intervention type: PROCEDURE
Intervention: Discectomy
Description: Discectomy refers to open temporomandibular joint surgery where the joint disc is completely removed without being replaced.
Study: NCT05964829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cionic Neural Sleeve NS-100
Description: The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph accelerometer
Description: Physical activity will be recorded using an Actigraph accelerometer worn on the non-dominant hip.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph accelerometer
Description: Physical activity will be recorded using an Actigraph accelerometer worn on the non-dominant hip.
Study: NCT06221254

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human therapist (Control)
Description: COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.
Study: NCT05865899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: valgus producing medial opening wedge high tibial osteotomy
Description: Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
Study: NCT06055231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vape device
Description: Consume THC via vape defice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint
Description: Consume THC via joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana via vape device
Description: Given via vape device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana via joint
Description: Given via joint
Study: NCT06504342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue-blocking glasses
Description: These lenses will filter \~10% of visible light across the visible light range (including in the range activating melanopsin) with complete blockade of ultraviolet light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses
Description: These lenses will filter \~10% of visible light across the visible light range (including in the range activating melanopsin) with complete blockade of ultraviolet light.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Avoid caloric food intake for a fourteen-hour period overnight from 6 p.m. to 8 a.m
Study: NCT05483543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
Study: NCT06504342

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-restricted eating
Description: Avoid caloric food intake for a fourteen-hour period overnight from 6 p.m. to 8 a.m

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lightly tinted glasses
Description: These lenses block shorter wavelengths of light, mainly ultraviolet light.
Study: NCT06493500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eggshell derived Nano-hydroxyapatite (n-HAp) with a Fluoride containing toothpaste
Description: patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
Study: NCT06627621

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Alveolar Ridge Reconstruction
Description: scaffold guided alveolar bone regeneration
Study: NCT06627387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training Using Augmented Reality
Description: The intervention will be carried out in two phases. The first phase will take place at Vall d\&amp;#39;Hebron Hospital, where patients will undergo balance training under the supervision of a physiotherapist. The scheduled dose will be 60 minutes daily, three days a week for four weeks. If the patients meet the inclusion criteria, the intervention will be extended for two more weeks at home. For this task, the involvement of a family member as a training partner will be essential. Relatives will receive training on using the system in the hospital and must be present whenever the patient undergoes the training at home. Three assessments will be carried out during the six weeks of the study. At the beginning of the intervention (Day 0 ), a second is once the hospital intervention has been carried out (Week 4 ), and the last is once the home intervention has been carried out (Week 6).
Study: NCT06493500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eggshell derived Nano-hydroxyapatite (n-HAp) with a Fluoride containing toothpaste
Description: patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eggshell derived Nano-hydroxyapatite (n-HAp) without a Fluoride containing toothpaste
Description: patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
Study: NCT04822922

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Description: The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Description: The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Description: The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.
Study: NCT05707845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical treatment.
Description: Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment.
Description: Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight reduction
Description: weight reduction in the form low caloric diet program for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
Study: NCT05803564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal aortic stent system
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
Study: NCT05441670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art and Physical Therapy
Description: 45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
Study: NCT05783401

Intervention type: OTHER
Intervention: Data acquisition: Speech acquisition
Description: Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.

Intervention type: OTHER
Intervention: Data acquisition: Speech acquisition
Description: Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.

Intervention type: DIAGNOSTIC_TEST
Intervention: Data acquisition: G8 Screening tool
Description: The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
Study: NCT05496699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mckenzie Exercises
Description: 1. Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~2. Cervical Rotation Exercise in Sitting Position~3. Cervical Retraction Exercise in Supine Position~4. Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~5. Cervical Lateral Flexion Exercise~6. Cervical Flexion Exercise in Sitting Position

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mulligan Exercise
Description: The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range.